HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others.
Leadership & Board
Key Executives
President and CEOMike Blue
Chief Operating OfficerChristine Gibbons
ChairmanJosh Makower
Chief Financial OfficerSamir Saini
Chief Medical OfficerMichael Laufer
Current Number of Employees390
Current LinkedIn Followers27,500
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$250M
Total Amount Raised$250M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$250M
Latest Funding Amount$250M
Latest Funding RoundGrowth Round
Latest Funding RoundGrowth Round
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
HistoSonics had 390 employees as of April 27, 2026. The number of employees increased by 8 (2.09%) week-over-week.
390Latest Employee Count
8(2.09%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
HistoSonics had 27,500 followers as of April 27, 2026. The number of followers increased by 431 (1.59%) week-over-week.
27,500Latest Followers Count
431(1.59%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.